

To be presented at the 6th Annual General Meeting
of Marinomed Biotech AG
on June 21, 2023

Declaration according to Sec. 87 Para. 2 Stock Corporation Act [AktG]

In accordance with Sec. 87 Para. 2 Stock Corporation Act, each person proposed for election to the Supervisory Board has to explain to the Annual General Meeting their expertise, their professional or comparable roles as well as all circumstances that could give cause for concern over bias.

As for my expertise and professional or comparable qualification I would like to refer to the enclosed CV which demonstrates that I have the skills required for membership in the Supervisory Board of Marinomed Biotech AG.

I herewith declare that

1. I have disclosed all circumstances in connection with Sec. 87 Para. 2 Stock Corporation Act, and that in my fair judgment there are no circumstances that could give cause for concern over bias,
2. I have not been convicted for any criminal act, including without limitation to criminal acts that may call my professional reliability into question according to Sec. 87 Para. 2a 3rd sentence Stock Corporation Act,
3. there are no impediments to my appointment in terms of Sec. 86 Para. 2, including Sec. 86 Para. 2 no. 1 and Sec. 86 Para. 3 Stock Corporation Act (exceeding the statutory maximum limit of supervisory board mandates) and Sec. 86 Para. 4 Stock Corporation Act,
4. I do not hold any corporate roles in other companies that are competing with Marinomed Biotech AG, and
5. I am not in a business or personal relationship with Marinomed Biotech AG or its Management Board that would create a material conflict of interest and would thus be capable of influencing my behaviour as a member of the Supervisory board.

Enclosure:
Curriculum Vitae

Uster, May 24, 2023

[Signature]

.....
Dr. Simon NEBEL, MBA

Simon NEBEL, PhD, MBA



WORK EXPERIENCE

2016 – ongoing **Viopas Venture Consulting GmbH**, Zurich (Switzerland)
Consulting company, strategy & finance advice for investors & companies

Managing Partner and Founder

2001 – ongoing **Aravis SA**, Zurich (Switzerland)
Investment advisory company, PE fund management for life science and renewable energy investments

Venture Partner (since 2016)

2018 – 2020 **Viopas Partners AG**, Zurich (Switzerland)
Boutique asset management firm, specialized in healthcare investments in public and private equities

Founding Partner

1997 - 2001 **UBS AG** (Basel, Zurich, London)
Corporate Centre & UBS Capital

Intern, Business Analyst

1993 - 1997 **Biocenter of the University of Basel** (Switzerland)
Biophysics department (Prof. Joachim Selig)

Postdoctoral Position

1988 - 1995 **Minerva**, Basel (Switzerland)
Private school preparing students for the Matura (Swiss equivalent of A levels)

Part-time teacher

BOARD MEMBERSHIPS

Life Science Companies:

- Marinomed Biotech AG (Austria), since 2008
- BirdRock Ltd. (Formerly: RuiYi/Anaphore Ltd.) (USA), since 2009
- Synaffix BV (The Netherlands), since 2013
- Bio-Sensing Solutions (DyCare) (Spain), since 2022
- Peleven Holding AG (Switzerland), since 2023

Fund Management or Investment Companies:

- Quadia SA (Switzerland), since 2023
- Hanaku AG (Switzerland), since 2023
- Aravis Biotech II GP AG (Switzerland), since 2010

EDUCATION

1999 - 2001	LONDON BUSINESS SCHOOL, London, UK MBA degree with distinction, with a focus on strategy and private equity
1993 - 1996	Biocenter, UNIVERSITY OF BASEL, Switzerland PhD in Biophysics
1988 - 1993	Biocenter, UNIVERSITY OF BASEL, Switzerland Master's Degree in Biology/Biophysics

LANGUAGES

German	Mother tongue
English	fluent
French	good conversation level

PERSONAL

Year of Birth	1966
Nationality	Swiss
Civil Status	married, two children